Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs.

Abstract

Manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies has matured significantly over the past decade, with improvements in automation, closed-system processing, and digital platforms enhancing reliability and scalability. Continuous process innovations and innovative manufacturing models are being explored and implemented, with an eye towards expanding patient access to this therapy and improving the patient journey. Manufacturing advances continue to be met with technical, operational, and regulatory challenges, including cost of goods, supply chain complexity, and capacity constraints, which underscore the need for continued innovation in process optimization and manufacturing models. This paper aims to cover considerations for a range of manufacturing models (including centralized, decentralized, and point-of-care manufacturing), analyze the manufacturing cost breakdown, and lay out opportunities for cost savings. Acknowledging the many variables in manufacturing, our analysis shows that, while there can be a big range of cost differentials between centralized and decentralized manufacturing approach, decentralization by itself is unlikely to be the main driver of cost reduction and may come with a decrease in manufacturing efficiency due to reduced scaling benefits. Many opportunities for cost reduction in manufacturing are present regardless of the manufacturing model. While cost reduction is a factor driving the uptake of this therapy, the potential of decentralized manufacturing lies in the improvements of access and patient experience, such as reduced and supply chain complexity associated with cell transport and shortened vein-to-vein times. The Alliance for Regenerative Medicine (ARM) supports all manufacturing models that can expand patient access to cell and gene therapies, while maintaining quality standards and regulatory compliance to ensure patient safety.